Korea's Ilyang Pharmaceutical Starts Phase III Trials For First-line CML Drug To Compete With Gleevec
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's Ilyang Pharmaceutical Co. Ltd. recently started Phase III trials for novel leukemia drug Supect (rodotinib) in Korea, India, Thailand, Philippines and Indonesia to determine whether it can gain approval in Korea as a first-line treatment for chronic myeloid leukemia and take on Novartis AG's Gleevec (imatinib). The company aspires to then bring the product to other Asian markets, and then eventually the U.S